We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: atrial fibrillation
MedXY News
EnglishTag

atrial fibrillation

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Active Monitoring for Atrial Fibrillation (AMALFI): Advancing Long-Term Remote Screening to Reduce Stroke Risk
Cardiologyatrial fibrillationstroke prevention

Active Monitoring for Atrial Fibrillation (AMALFI): Advancing Long-Term Remote Screening to Reduce Stroke Risk

By MedXY|Oct 21, 2025

The AMALFI trial evaluates remote screening for asymptomatic atrial fibrillation in older adults to improve detection, anticoagulation use, and reduce stroke risk, with findings pending follow-up at 2.5 and 5 years.

Remote ECG Patch Screening for Asymptomatic Atrial Fibrillation: Insights from the AMALFI Trial
Cardiologyatrial fibrillationscreening

Remote ECG Patch Screening for Asymptomatic Atrial Fibrillation: Insights from the AMALFI Trial

By MedXY|Oct 21, 2025

The AMALFI trial demonstrates that remote, mail-based 14-day ECG patch screening modestly increases long-term atrial fibrillation detection and anticoagulation use in older adults at stroke risk, with no observed reduction in stroke at 2.5

Reevaluating New-Onset Atrial Fibrillation After CABG: Insights from Long-Term Continuous Monitoring
Cardiologyanticoagulationatrial fibrillation

Reevaluating New-Onset Atrial Fibrillation After CABG: Insights from Long-Term Continuous Monitoring

By MedXY|Oct 10, 2025

A multicenter prospective study reveals a higher incidence but very low burden of new-onset atrial fibrillation post-CABG, challenging current anticoagulation guidelines.

Age-Stratified Outcomes of Rivaroxaban Monotherapy in Atrial Fibrillation with Stable Coronary Artery Disease: Insights from the AFIRE Trial
Clinical UpdatesAntithrombotic Therapyatrial fibrillation

Age-Stratified Outcomes of Rivaroxaban Monotherapy in Atrial Fibrillation with Stable Coronary Artery Disease: Insights from the AFIRE Trial

By MedXY|Sep 27, 2025

This post hoc AFIRE trial analysis shows rivaroxaban monotherapy reduces major cardiovascular events and major bleeding across age groups in AF with stable CAD, with notable age-related efficacy and safety trends warranting further research

Abelacimab Shows Consistent Bleeding Safety Across Kidney Function in Atrial Fibrillation: Insights from the AZALEA-TIMI 71 Trial
CardiologyAbelacimabatrial fibrillation

Abelacimab Shows Consistent Bleeding Safety Across Kidney Function in Atrial Fibrillation: Insights from the AZALEA-TIMI 71 Trial

By MedXY|Oct 9, 2025

This analysis of the AZALEA-TIMI 71 trial reveals that abelacimab, a novel factor XI inhibitor, significantly reduces bleeding risk versus rivaroxaban in atrial fibrillation patients, regardless of kidney function, suggesting its promise fo

Rivaroxaban vs Warfarin in Postcardiac Surgery Atrial Fibrillation: Insights from the NEW-AF Trial
Cardiologyanticoagulationatrial fibrillation

Rivaroxaban vs Warfarin in Postcardiac Surgery Atrial Fibrillation: Insights from the NEW-AF Trial

By MedXY|Oct 9, 2025

The NEW-AF trial compared rivaroxaban and warfarin in new-onset atrial fibrillation after cardiac surgery, finding no difference in length of hospital stay but greater patient convenience and similar safety with rivaroxaban.

Catheter Ablation vs Drug Therapy for Atrial Fibrillation: Insights from the CABANA Trial by Nonmodifiable Risk Profiles
Cardiologyatrial fibrillationcatheter ablation

Catheter Ablation vs Drug Therapy for Atrial Fibrillation: Insights from the CABANA Trial by Nonmodifiable Risk Profiles

By MedXY|Oct 7, 2025

This secondary analysis of the CABANA trial reveals catheter ablation significantly benefits AF patients with fewer than three nonmodifiable recurrence risk factors, underscoring the potential for personalized treatment strategies.

Impact of Diabetes and Obesity on Early Rhythm Control Outcomes in Atrial Fibrillation: Insights from the EAST-AFNET 4 Trial
Cardiologyatrial fibrillationdiabetes

Impact of Diabetes and Obesity on Early Rhythm Control Outcomes in Atrial Fibrillation: Insights from the EAST-AFNET 4 Trial

By MedXY|Oct 7, 2025

A secondary analysis of the EAST-AFNET 4 trial shows early rhythm control therapy effectively reduces cardiovascular events in atrial fibrillation patients regardless of diabetes status or obesity, supporting its broad clinical use.

Serum Carboxymethyl-Lysine and Its Prospective Associations with Heart Failure and Atrial Fibrillation in Older Adults: Insights from the Cardiovascular Health Study
Cardiologyatrial fibrillationgeriatric cardiology

Serum Carboxymethyl-Lysine and Its Prospective Associations with Heart Failure and Atrial Fibrillation in Older Adults: Insights from the Cardiovascular Health Study

By MedXY|Oct 6, 2025

Serum advanced glycation end-product carboxymethyl-lysine (CML) is linked to higher risks of heart failure and atrial fibrillation in older adults, highlighting potential therapeutic targets against AGE-related cardiac dysfunction.

Biomarker-Guided ABC-AF Risk Scores: Evaluating Their Role in Personalized Therapy for Atrial Fibrillation
Clinical UpdatesABC-AF Risk Scoreatrial fibrillation

Biomarker-Guided ABC-AF Risk Scores: Evaluating Their Role in Personalized Therapy for Atrial Fibrillation

By MedXY|Sep 6, 2025

A large randomized study found that biomarker-based ABC-AF risk score-guided therapy did not improve stroke or death outcomes versus usual care in atrial fibrillation, highlighting the need for rigorous prospective validation of precision m

Biomarker-Guided ABC-AF Risk Scores in Atrial Fibrillation: Insights from a Large Multicenter Randomized Trial
CardiologyABC-AF Risk Scoreatrial fibrillation

Biomarker-Guided ABC-AF Risk Scores in Atrial Fibrillation: Insights from a Large Multicenter Randomized Trial

By MedXY|Oct 6, 2025

A biomarker-based ABC-AF risk score-guided treatment did not improve stroke or death outcomes versus standard care in atrial fibrillation, underscoring the need for prospective validation of precision medicine tools before clinical implemen

Low-Dose Digoxin Enhances Cardiac Function in Heart Failure with Preserved EF and Atrial Fibrillation: Insights from the RATE-AF Trial
Cardiologyatrial fibrillationheart failure

Low-Dose Digoxin Enhances Cardiac Function in Heart Failure with Preserved EF and Atrial Fibrillation: Insights from the RATE-AF Trial

By MedXY|Oct 6, 2025

The RATE-AF trial demonstrates that low-dose digoxin significantly improves systolic function and symptoms in patients with heart failure, preserved ejection fraction, and permanent atrial fibrillation compared to beta-blockers, with fewer

Reevaluating Long-Term Anticoagulation After Atrial Fibrillation Ablation: Insights from the ALONE-AF Randomized Trial
Cardiologyatrial fibrillationcatheter ablation

Reevaluating Long-Term Anticoagulation After Atrial Fibrillation Ablation: Insights from the ALONE-AF Randomized Trial

By MedXY|Dec 12, 2025

The ALONE-AF trial reveals that discontinuation of oral anticoagulants post-successful atrial fibrillation ablation may reduce stroke, systemic embolism, and major bleeding compared to continued therapy, informing anticoagulation strategies

Epicardial Adipose Tissue as a Predictor of New-Onset Atrial Fibrillation: Insights from a Danish Population Cohort
Cardiologyatrial fibrillationCardiovascular risk factors

Epicardial Adipose Tissue as a Predictor of New-Onset Atrial Fibrillation: Insights from a Danish Population Cohort

By MedXY|Oct 5, 2025

This Danish cohort study demonstrates that increased epicardial adipose tissue volume independently elevates the risk of new-onset atrial fibrillation, highlighting the importance of fat distribution beyond BMI in cardiovascular risk assess

Dynamic Triglyceride-Glucose Index Trajectories as Predictors of Mortality in Critically Ill Patients with Atrial Fibrillation
Cardiologyatrial fibrillationinsulin resistance

Dynamic Triglyceride-Glucose Index Trajectories as Predictors of Mortality in Critically Ill Patients with Atrial Fibrillation

By MedXY|Oct 4, 2025

A retrospective study shows high and fluctuating triglyceride-glucose (TyG) index trajectories predict increased short- and long-term mortality in ICU patients with atrial fibrillation, highlighting TyG dynamics as a valuable prognostic bio

Dynamic Triglyceride-Glucose Index Trajectories Predict Mortality in Critically Ill Atrial Fibrillation Patients
Cardiologyatrial fibrillationICU

Dynamic Triglyceride-Glucose Index Trajectories Predict Mortality in Critically Ill Atrial Fibrillation Patients

By MedXY|Oct 4, 2025

This study reveals that fluctuating high triglyceride-glucose (TyG) index trajectories in critically ill atrial fibrillation patients significantly predict increased all-cause mortality up to one year post-ICU admission, offering a novel pr

Optimizing Anticoagulant Therapy in Frail Elderly AF Patients: Insights from the COMBINE-AF Substudy
Cardiologyanticoagulationatrial fibrillation

Optimizing Anticoagulant Therapy in Frail Elderly AF Patients: Insights from the COMBINE-AF Substudy

By MedXY|Oct 3, 2025

Switching frail, elderly atrial fibrillation patients from warfarin to standard-dose DOAC reduced stroke, fatal and intracranial bleeding, and death, though gastrointestinal bleeding increased. Major bleeding and net clinical outcome remain

Marshall-Plan Ablation Strategy Versus Pulmonary Vein Isolation in Persistent AF
Cardiologyatrial fibrillationCardiology

Marshall-Plan Ablation Strategy Versus Pulmonary Vein Isolation in Persistent AF

By MedXY|Oct 3, 2025

This study compares the effectiveness of the Marshall-Plan ablation strategy against pulmonary vein isolation for treating persistent atrial fibrillation.

Higher Risk of Major Gastrointestinal Bleeding with Edoxaban vs Warfarin After TAVR: Insights from the ENVISAGE-TAVI AF Trial
Cardiologyatrial fibrillationEdoxaban

Higher Risk of Major Gastrointestinal Bleeding with Edoxaban vs Warfarin After TAVR: Insights from the ENVISAGE-TAVI AF Trial

By MedXY|Oct 3, 2025

The ENVISAGE-TAVI AF trial found that patients with atrial fibrillation undergoing TAVR had a higher incidence of major gastrointestinal bleeding when treated with edoxaban compared to warfarin, highlighting the importance of risk factor id

Optimizing Sedation for Pulsed-Field Ablation in Atrial Fibrillation: Results of the COOPERATIVE-PFA Trial
CardiologyAnesthesiaatrial fibrillation

Optimizing Sedation for Pulsed-Field Ablation in Atrial Fibrillation: Results of the COOPERATIVE-PFA Trial

By MedXY|Oct 3, 2025

This randomized trial compares sedation regimens for pulsed-field ablation in atrial fibrillation, finding remimazolam-ketamine deep analgosedation superior to propofol-opioid approaches in reducing hypoxemia and hypotension.

Prev
5 / 6
1…3456
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities